each saw the clock advance an hour, with no major setbacks and plans beginning to fall into place for distributing an eventual vaccine.
All the companies are contractually obligated to produce at least 100 million doses of vaccine in return for funding. But all those doses won't all be available the first day a vaccine gets a thumbs up from the U.S. Food and Drug Administration. once a vaccine is secured, it may be difficult to convince tens of thousands of people to volunteer to test a 2.0 or 3.0 version.
Waning public interest after a first COVID-19 vaccine is approved could mean that"some of these vaccine trials trailing behind will have to close," said Dr. Monica Gandhi, a professor of medicine and infectious disease expert at the University of California-San Francisco. "From my interactions with some county and state public health agencies, they are trying to get their plans organized," she said. "But without knowing which or how many vaccines will make it successfully though, it is a challenge to plan."
Trial pauses are relatively routine, “so nothing necessarily to worry about in terms of vaccine safety,” Bjorkman said. “It shows, however, that testing vaccines should be done carefully and without skipping any safety standards.”USA TODAY received responses from 15 scientists and researchers, asking how far they think the vaccine development effort has progressed since Jan. 1, when the virus was first internationally recognized.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: HuffPostWomen - 🏆 27. / 68 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: ABC - 🏆 471. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: CNN - 🏆 4. / 95 Read more »